A low expression of CCL19 in CRC is related to tumor angiogenesis, and a high expression of CCL19 inhibits CRC angiogenesis by promoting miR-206, thus inhibiting the Met/ERK/Elk-1/HIF-1α/VEGF-A pathway (55). Here, CCL19 is linked to neoplasm.